A phase 3 pivotal trial of AGB101 to slow progression in MCI due to alzheimer's disease
Ended Project Grant Awarded Last action
- Award ID
- R56AG055416
- Recipient
-
Agenebio, Inc. UEI YZWJGZMT3MN5
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,998,393
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- Baltimore, MD 21218, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | -$1,607 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $4,000,000 |
Quick answers
Who received award R56AG055416?
R56AG055416 was awarded to Agenebio, Inc. by National Institute on Aging (National Institutes of Health) on September 15, 2017.
How much is award R56AG055416 worth?
$3,998,393 has been obligated on R56AG055416.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award